Breaking News: Unveiling the First Comprehensive Guide for Stomach Cancer Radiation Therapy
ARLINGTON, Va., November 18, 2025 - A groundbreaking development in the fight against gastric cancer has emerged, with the American Society for Radiation Oncology (ASTRO) releasing its inaugural clinical guideline focused solely on radiation therapy for this complex disease. This guideline, published in Practical Radiation Oncology, aims to clarify the role of radiation therapy at every stage of gastric cancer, offering a comprehensive roadmap for healthcare professionals and patients alike.
The Global Impact of Gastric Cancer
Gastric tumors pose a significant health challenge, ranking as the fifth most common cause of cancer incidence and death worldwide. Despite an overall decline in stomach cancer rates over the past half-century, recent studies suggest a potential increase among middle-aged adults. The complexity of gastric cancer often lies in its advanced stage at diagnosis, necessitating a multidisciplinary approach involving radiation, surgical, and medical oncology.
Advancements in Treatment: A Decade of Progress
The past decade has witnessed remarkable advancements in gastric cancer treatment, driven by improvements in surgery, chemotherapy, immunotherapy, and radiation therapy. For patients with resectable disease, perioperative chemotherapy regimens administered before and after surgery have shown enhanced survival rates, with emerging evidence highlighting the additional benefits of immunotherapy integration. For those unable to undergo perioperative chemotherapy, a preoperative chemoradiation approach may offer effective local control, while definitive chemoradiation provides a non-surgical option for medically inoperable patients or those opting against surgery.
Furthermore, radiation therapy plays a crucial palliative role in managing gastric cancer-related symptoms such as bleeding and pain. Modern techniques have enabled more precise and better-tolerated treatments, further enhancing the quality of life for patients.
Expert Insights: Navigating the Evolving Landscape
Christopher G. Willett, MD, FASTRO, chair of the expert panel and the Mark W. Dewhirst Professor of Radiation Oncology at Duke University, emphasizes the complexity and multidisciplinary nature of gastric cancer management. He highlights the evolving role of radiation therapy over the past two decades, requiring dynamic integration with surgical, chemotherapy, immunotherapy, and palliative care modalities.
Christopher J. Anker, MD, vice chair of the expert panel and a professor of radiation oncology at the University of Vermont Cancer Center, adds that while other societies have published gastric cancer treatment guidelines, ASTRO's guideline is the first to comprehensively address the role of radiation therapy across all disease stages. It provides patient-centered, evidence-based recommendations to guide clinical practice, filling a critical gap in the literature.
Key Recommendations: A Comprehensive Overview
Resectable Disease:
- Surgery and perioperative chemotherapy (fluorouracil, oxaliplatin, and docetaxel (FLOT) given before and after surgery) are recommended for resectable gastric cancer patients.
- Pre-surgical radiation therapy with concurrent chemotherapy is advised for those ineligible for perioperative chemotherapy, aiding in achieving negative surgical margins and reducing early recurrence risks.
- Pre-surgical chemoradiation may be added to perioperative chemotherapy for borderline resectable tumors, improving the chances of complete cancer removal.
- The guideline also explores the evolving role of immunotherapy as a first-line treatment and the use of chemoradiation therapy post-surgery for select patients.
Unresectable (Locally Advanced or Metastatic) Disease:
- Definitive radiation therapy with concurrent chemotherapy is recommended for nonmetastatic gastric cancer patients declining or ineligible for surgery.
- It may be considered for patients with inoperable recurrent gastric cancer if the recurrence is localized or locoregional and no prior radiation therapy was administered.
- The guideline includes a treatment algorithm for managing locally advanced disease.
- For locally advanced or metastatic cancer, palliative radiation therapy is advised to alleviate bleeding, pain, obstruction, and other symptoms. Reirradiation may also be considered in the palliative setting for some patients.
- For cancer metastasized to a limited number of sites outside the stomach, radiation therapy or surgery for all visible metastases combined with systemic therapy is conditionally recommended. The role of radiation therapy on the primary tumor for patients with stable or regressing metastases to control symptoms is also discussed.
Treatment Planning and Delivery:
- Recommendations cover optimal dosing and fractionation approaches for different gastric cancer stages and outline suggested treatment volumes to maximize precision and minimize side effects.
- The guideline discusses best practices for treatment planning and delivery of definitive and palliative radiation therapy, including newer techniques like intensity-modulated radiation therapy, image guidance, and respiratory management, which enhance treatment tolerance and fidelity.
- Care decisions should involve providers from all treating disciplines and the patient, with a comprehensive discussion of risks and benefits to determine the best treatment approach.
About the Guideline:
"Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline" was developed by a multidisciplinary panel comprising radiation, medical, and surgical oncologists, a radiation oncology resident, a medical physicist, and a patient representative. Recommendations are based on a systematic review of research published from 2001 to mid-2025.
The guideline was developed in collaboration with the American Society of Clinical Oncology, the European Society for Radiotherapy and Oncology (ESTRO), and the Society of Surgical Oncology (SSO). It is endorsed by ESTRO, SSO, the Royal Australian and New Zealand College of Radiologists, and the American Radium Society.
ASTRO's clinical guidelines serve as tools to promote individualized, shared decision-making between physicians and patients. They should not be construed as strict or superseding the informed judgments of individual healthcare professionals and patients.
Patient Resources:
For patients seeking information on treatment options, RTAnswers.org provides valuable resources:
- General information: Radiation Therapy for Esophagus and Stomach Cancers
- Video: Radiation Therapy for Upper GI Cancers
- Video: An Introduction to Radiation Therapy
- PDF: Radiation Therapy for Cancers of the Esophagus and Stomach
- PDF: Side Effects Chart
About ASTRO:
The American Society for Radiation Oncology (ASTRO) is the world's largest professional society dedicated to advancing radiation oncology. With over 10,000 members, including physicians, nurses, physicists, radiation therapists, dosimetrists, and other professionals, ASTRO is committed to improving patient outcomes through clinical care, research, education, and policy advocacy. Radiation therapy plays a vital role in 40% of cancer cures worldwide, with over one million Americans receiving radiation treatments annually. For more information, visit ASTRO's website and media center, and connect with them on social media.
